Dr. Mills weighs in on the benefits of testosterone enanthate
“There's 3 different levels of dosing…so this does provide you with a mechanism for titration if you're going to be using that in your patients,” says Jesse N. Mills, MD.
In this video, Jesse N. Mills, MD, discusses the important findings from the study, “Subcutaneous Testosterone Enanthate and the Effect of Body Mass Index on Serum Testosterone in Men with Testosterone Deficiency,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Mills is an associate clinical professor of urology at the David Geffen School of Medicine, the director of the UCLA division of Andrology, the director of the Men’s Clinic and the chief of UCLA Santa Monica Urology, University of California, Los Angeles
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.
